A Kinomic Approach to Identify Signaling Proteins Involved in Drug Resistance in GastroEnteroPancreatic Neuroendocrine Tumors Abstract #1739

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) result in tumour growth stabilization, eventually followed by tumour progression. Thus, despite their original characteristics, NETs exhibit similar resistance features to treatments than other more common tumours.
Aim(s): We aim at identifying signaling partners responsible of acquired resistance to treatments in order to develop drug combinations to prevent resistance occurence.
Materials and methods: We engineered NETs cell lines, BON-1 and QGP-1, resistant to a chemotherapeutic agent, Oxaliplatin, and to an mTor inhibitor, Everolimus, by chronically exposing them to the drugs. We are using microarray-based kinomics to obtain highthroughput kinase activity profiles from drug sensitive vs resistant cells.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr David Romano

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis
#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors
Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr David Romano
Authors: Romano D, Gerard C, Poizat F, Niccoli P, ...
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2898 Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction: The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Assistant Profes Po Hien Ear
Authors: Ear P H, Tran C, Li G, Kaemmer C, ...
#2142 Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Introduction: Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: PhD Jennifer Wietzke